![]() The Nuffield Department of Population Health at the University of Oxford has a staff policy of not accepting honoraria or consultancy fees directly or indirectly from industry (see ). All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. No form of payment was given to anyone to produce the manuscript. The authors have no conflict of interest or financial relationships relevant to the submitted work to disclose. ![]() 38% risk ratio 0♸5 95% CI 0♷8-0♹3 p=0♰005).įunding UK Research and Innovation (Medical Research Council) and National Institute of Health Research (Grant ref: MC_PC_19056). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (33% vs. Patients allocated to tocilizumab were more likely to be discharged from hospital alive within 28 days (54% vs. ![]() In particular, a clear mortality benefit was seen in those receiving systemic corticosteroids. Consistent results were seen in all pre-specified subgroups of patients. ![]() Overall, 596 (29%) of the 2022 patients allocated tocilizumab and 694 (33%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0♸6 95% confidence interval 0♷7-0♹6 p=0♰07). Median CRP was 143 mg/L and 3385 (82%) patients were receiving systemic corticosteroids at randomisation. Findings Between 23 April 2020 and 24 January 2021, 4116 adults were included in the assessment of tocilizumab, including 562 (14%) patients receiving invasive mechanical ventilation, 1686 (41%) receiving non-invasive respiratory support, and 1868 (45%) receiving no respiratory support other than oxygen. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |